ASSESSMENT OF LOWER URINARY TRACT SYMPTOMS IN BENIGN PROSTATIC HYPERPLASIA TREATED BY CONSERVATIVE MANAGEMENT
DOI:
https://doi.org/10.22159/ajpcr.2024v17i12.52568Keywords:
Effectiveness, Benign prostatic hyperplasia, International prostate symptom score, Quality of lifeAbstract
Objective: The objective of the study is to evaluate the effectiveness of prescribed drug therapy for patients with benign prostatic hyperplasia (BPH) and to analyze the quality of life (QOL) of these patients.
Methods: A prospective observational study was conducted over 1 year, from October 2019 to September 2020, aiming to assess the effectiveness of medications used in BPH treatment. Urine flow was measured at each follow-up visit using an uroflow meter to evaluate treatment effectiveness. The American Urological Association’s QOL and the International Prostate Symptom Score (IPSS) were utilized to assess patients’ QOL.
Results: Out of 250 patients screened, 138 were eligible for the study, with 82 (59.43%) in the 60–80 age group. A total of 1212 medications were prescribed, with alpha-adrenergic blockers and 5-alpha reductase inhibitors (5-ARIs) making up 34.08% of all prescriptions. Urine flow increased from 13.42 mL/s at the first visit to 14.46 mL/s at the second visit, reaching 15.62 mL/s by the third visit. The IPSS score decreased from 15.44 at the first visit to 13.51 at the second and further to 12.28 at the third.
Conclusion: Alpha-adrenergic blockers such as tamsulosin (30.12%) and silodosin (3.96%), along with the 5-ARI dutasteride (0.50%), were prescribed for BPH treatment. A statistically significant improvement (p<0.05) in lower urinary tract symptoms and QOL was observed at each follow-up visit.
Downloads
References
Yu ZJ, Yan HL, Xu FH, Chao HC, Deng LH, Xu XD, et al. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Front Pharmacol. 2020;11:658. doi: 10.3389/fphar.2020.00658, PMID 32457631
Lee C, Kozlowski JM, Grayhack JT. Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate. 1997;31:131-8. doi: 10.1002/(sici)1097-0045, PMID 9140127
Campbell-Wash, Wein AJ, Kavoussi RL, Partin WA, Peters CA. In: Alan J, editors.. 11th ed. Netherlands: Elsevier Publishers; 2016. p. 2467-70.
D’Silva KA, Dahm P, Wong CL. Does this man with lower urinary tract symptoms have bladder outlet obstruction?: The rational clinical examination: A systematic review. JAMA. 2014;312(5):535-42. doi: 10.1001/jama.2014.5555, PMID 25096693
McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793-803. doi: 10.1016/j.juro.2011.01.074, PMID 21420124
WHO. Global Health Observatory (GHO) Data. Available from: https:// www.who.int/gho/mortality_burden_disease/life_tables/situation_ trends_texten [Last accessed on 2019 Jul 25].
Sabnis RB, Rajeev TP, Sinha S, Aneesh S, Mittal R. Survey by urological society of India (USI) to understand practice patterns in diagnosis and medical management of voiding LUTS secondary to benign prostatic obstruction (BPO). Int J Sci Res. 2019;8(5):18-21.
Suzuki H, Yano M, Awa Y, Nakatsu H, Egoshi KI, Mikami K, et al. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: Using international prostate symptom score and rand medical outcomes study 36-item health survey: Tamsulosin on QOL for BPH patients. Int J Urol. 2006;13(9):1202-6. doi: 10.1111/j.1442-2042.2006.01594.x, PMID 16984553
Zhou Z, Cui Y, Wu J, Ding R, Cai T, Gao Z. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. BMC Urol. 2019 Mar 11;19(1):17. doi: 10.1186/s12894- 019-0446-8, PMID 30871552
Schulman CC, Lock TM, Buzelin JM, Boeminghaus F, Stephenson TP, Talja M, et al. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol. 2001 Oct;166(4):1358- 63. doi: 10.1016/S0022-5347(05)65769-2, PMID 11547074.
Hutchison A, Farmer R, Verhamme K, Berges R, Navarrete RV. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol. 2007 Jan;51(1):207-15. doi: 10.1016/j. eururo.2006.06.012, PMID 16846678
Tomar V, Bhati BS, Datta B, Bellamkonda L, Prajapati HK, Chaturvedi A, et al. Prescription pattern of alpha blockers in the treatment of benign prostatic hyperplasia in India: A paper based survey. Int J Basic Clin Pharmacol. 2020;9(2):348. doi: 10.18203/2319-2003.ijbcp20200189
Pramana IB, Oka AA, Duarsa GW, Santosa KB, Yudiana IW, Tirtayasa PM, et al. The effectiveness of tamsulosin in benign prostate hyperplasia (BPH) patients with lower urinary tract symptoms (LUTS): A multi-centre cohort retrospective study. IJBS. 2020;14(1):17-20. doi: 10.15562/ijbs.v14i1.214
Published
How to Cite
Issue
Section
Copyright (c) 2024 Dr. Pooja Ranpariya, Dr. Anil P Singh, Dr. Saurin Modi
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
